{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:00:25Z","timestamp":1781154025367,"version":"3.54.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"\n Background<\/jats:title>\n Differentiated advanced thyroid carcinoma (DATC) is rare, accounting for ~5% of thyroid tumors, including radioiodine-refractory thyroid tumors (RAI-R-TC) and thyroid tumors not amenable to thyroidectomy. Prognosis is poor, with a 10-year survival of ~10% and median life expectancy of 3\u20135 years. Systemic therapies are often required, but management remains challenging due to comorbidities and treatment-related toxicity. In particular, it is unknown whether outcomes differ between patients with predominantly locoregional disease and those with distant metastases.<\/jats:p>\n <\/jats:sec>\n \n Patients and methods<\/jats:title>\n We retrospectively analyzed a consecutive series of 43 patients with RAI-R-TC treated with tyrosine kinase inhibitors (TKIs). Patients were stratified according to the predominant site of disease involvement at TKI initiation: (i) locoregional progression with involvement of critical cervical structures, and (ii) progressive distant metastatic disease. Tumor response and disease progression were defined according to RECIST 1.1 criteria. Disease-specific survival (DSS) was estimated using the Kaplan-Meier method, and differences between the two groups were assessed using the log-rank test.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Median age at diagnosis was 63.3 years; 51.2% patients were females. Histology included papillary (n=26), follicular (n=10), poorly differentiated (n=6), and papillary\u2013follicular (n=1). At presentation or shortly after, 44.2% patients had distant metastases; 55.8% had locally advanced disease, of whom 91.7% also developed distant spread. Patients with locoregional disease demonstrated significantly worse disease-specific survival compared with those presenting with distant metastases (p &lt; 0.05). At last follow-up, 51.2% were stable, 11.6% progressed, 62.8% were alive, and 37.2% had died of disease. The difference in survival between the two groups was statistically significant.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Despite belonging to the same disease entity, our preliminary data suggest that DATC patients show divergent prognostic outcomes depending on disease extent. Locoregional invasion appears to carry a particularly poor outcome, underscoring the need for differentiated and personalized therapeutic strategies. TKIs remain effective in both settings, but tailored management is warranted to address the distinct challenges of locoregional versus distant metastatic disease.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fendo.2026.1824512","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:40:47Z","timestamp":1781152847000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Disease site as an independent predictor of survival in radioiodine-refractory thyroid cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Giulia","family":"Sapuppo","sequence":"first","affiliation":[{"name":"Endocrinology Section, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Hospital","place":["Catania, Italy"]},{"name":"Medical Oncology Unit, Istituto Clinico Humanitas","place":["Catania, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Russo","sequence":"additional","affiliation":[{"name":"Endocrinology Section, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Hospital","place":["Catania, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grete Francesca","family":"Privitera","sequence":"additional","affiliation":[{"name":"Bioinformatics Unit, Department of Clinical and Experimental Medicine, University of Catania","place":["Catania, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Massimino","sequence":"additional","affiliation":[{"name":"Department of General Surgery and Medical-Surgical Specialties, University of Catania","place":["Catania, Italy"]},{"name":"Center of Experimental Oncology and Hematology, A.O.U. Policlinico \u201cG. Rodolico-S. Marco\u201d","place":["Catania, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Piana","sequence":"additional","affiliation":[{"name":"Diagnostic and Interventional Radiology Unit National Relevance and Highly Specialized Hospital (ARNAS) Garibaldi - Nesima","place":["Catania, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"Trovato","sequence":"additional","affiliation":[{"name":"Surgical Oncology, Garibaldi-Nesima Medical Center","place":["Catania, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusi","family":"Blanco","sequence":"additional","affiliation":[{"name":"Oncology Unit, Garibaldi-Nesima Hospital","place":["Catania, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Adinolfi","sequence":"additional","affiliation":[{"name":"Endocrinology Section, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Hospital","place":["Catania, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Romano","sequence":"additional","affiliation":[{"name":"Endocrinology Section, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Hospital","place":["Catania, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Pellegriti","sequence":"additional","affiliation":[{"name":"Endocrinology Section, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Hospital","place":["Catania, Italy"]},{"name":"Medical Oncology, Department of Clinical and Experimental Medicine, University of Catania","place":["Catania, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1159\/000502229","article-title":"2019 European Thyroid Association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer","volume":"8","author":"Fugazzola","year":"2019","journal-title":"Eur Thyroid J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00035-3","article-title":"The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020","volume":"10","author":"Pizzato","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-21-1440","article-title":"Cancer progress and priorities: Epidemiology of thyroid cancer","volume":"31","author":"Kitahara","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1056\/NEJMc1503150","article-title":"Lenvatinib in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.71.6472","article-title":"Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial","volume":"35","author":"Brose","year":"2017","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1530\/ERC-18-0049","article-title":"Prolonged duration of response in lenvatinib responders with thyroid cancer","volume":"25","author":"Gianoukakis","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0549","article-title":"Defining radioiodine-refractory differentiated thyroid cancer: Efficacy and safety of lenvatinib by radioiodine-refractory criteria in the SELECT trial","volume":"27","author":"Kiyota","year":"2017","journal-title":"Thyroid"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): A phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B12","article-title":"Common terminology criteria for adverse events (CTCAE) v5.0. U.S. Department of Health and Human Services, National Institutes of Health","year":""},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ecl.2018.10.002","article-title":"Evolving understanding of the epidemiology of thyroid cancer","volume":"48","author":"Seib","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejca.2019.05.031","article-title":"Real-world efficacy and safety of lenvatinib: Data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy","volume":"118","author":"Locati","year":"2019","journal-title":"Eur J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8834148","article-title":"Real-world data for lenvatinib in radioiodine-refractory differentiated thyroid cancer (RELEVANT): A retrospective multicentric analysis of clinical practice in Austria","volume":"2020","author":"Rendl","year":"2020","journal-title":"Int J Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0428","article-title":"Perspective: The molecular landscape of radioactive iodine refractory differentiated thyroid cancer and poorly differentiated thyroid cancer","volume":"33","author":"Shobab","year":"2023","journal-title":"Thyroid\u00ae"},{"key":"B18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.24911\/PJNMed.175-1672931077","article-title":"Clinical utility of BRAF and pTERT mutations in precision management of papillary thyroid cancer","volume":"13","author":"Shabbir","year":"2023","journal-title":"Pak J Nucl Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.24911\/PJNMed.175-1701839619","article-title":"Unveiling thyroid cancer precision: Significance of molecular markers for risk stratification and management","volume":"14","author":"Shabbir","year":"2024","journal-title":"Pak J Nucl Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.24911\/PJNMed.175-1759299254","article-title":"A pilot study on the prevalence of BRAF V600E mutation in papillary thyroid carcinoma in the Pakistani population","volume":"15","author":"Shabbir","year":"2025","journal-title":"Pak J Nucl Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-021-02634-z","article-title":"Long-term management of lenvatinib-treated thyroid cancer patients: A real-life experience at a single institution","volume":"73","author":"Porcelli","year":"2021","journal-title":"Endocrine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03638-7","article-title":"Real-world treatment patterns and clinical outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated with first line lenvatinib monotherapy in the United States","volume":"84","author":"Worden","year":"2024","journal-title":"Endocrine"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02245-0","article-title":"Locally unresectable differentiated thyroid cancer: Outcomes and perspectives","volume":"69","author":"Lamartina","year":"2020","journal-title":"Endocrine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.04.009","article-title":"ESMO clinical practice guideline update on the use of systemic therapy in advanced thyroid cancer","volume":"33","author":"Filetti","year":"2022","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"153\u201361","DOI":"10.1177\/10507256251409138","article-title":"Real-world experience with lenvatinib plus pembrolizumab in metastatic BRAF wild-type anaplastic thyroid carcinoma","volume":"36","author":"Hamidi","year":"2024","journal-title":"Thyroid"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.011","article-title":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Machiels","year":"2020","journal-title":"Ann Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw329","article-title":"Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Lordick","year":"2016","journal-title":"Ann Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-008-0241-3","article-title":"Undertreatment of tracheal carcinoma: Multidisciplinary audit of epidemiologic data","volume":"16","author":"Honings","year":"2009","journal-title":"Ann Surg Oncol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1824512\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:40:51Z","timestamp":1781152851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1824512\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":28,"alternative-id":["10.3389\/fendo.2026.1824512"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1824512","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"article-number":"1824512"}}